Scancell Holdings Company Description

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom.

The company’s product candidates include ImmunoBody, DNA active immunotherapies encode a protein in the form of a modified antibody; Moditope, a potent peptide active immunotherapy targeting tumour-specific neoantigens through the MHC-II presentation pathway; SCIB1 which is in phase I for adjuvant melanoma; SCIB1/iSCIB1+ that is in Phase III for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer.

It also develops Modi-1, an active peptide immunotherapy that is in phase III clinical trials for the treatment of solid tumors, including renal cell carcinoma, head, and neck; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination.

In addition, the company offers GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which promotes receptor clustering thereby improving immune signaling.

Further, it provides pre-clinical products, such as SC129 and SC2811 for solid tumors; SC27; and GT 200 for ovarian cancer.

Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.

Scancell Holdings plc

Country	United Kingdom
Founded	1996
Industry	Biotechnology
Sector	Healthcare
Employees	55
CEO	Phillip L’Huillier

Contact Details

Address: Bellhouse Building Oxford, OX4 4GD United Kingdom
Phone	44 18 6558 2066
Website	scancell.co.uk

Stock Details

Ticker Symbol	SCLP
Exchange	London Stock Exchange AIM
Fiscal Year	May - April
Reporting Currency	GBP
ISIN Number	GB00BX8KRW34
SIC Code	2836

Key Executives

Name	Position
Phillip L’Huillier	Chief Executive Officer
David Schilansky	Chief Financial Officer